VM202 selected as Biostar research project

Published: 2008-10-31 06:52:00

Updated: 2008-10-31 06:52:00

The ministry of Knowledge Economy has announced that ViroMed Co.’s VM202 (DNA-based medicine for ischemic disease including peripheral and coronary artery disease) has been designated as one of the nation’s Biostar research projects in 2008.

The government plans to spend a 50-billion research ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK